ImmunityBio Shares Fall 15% Following Third Quarter Earnings Miss
ImmunityBio (IBRX) saw its stock price drop approximately 15% following third-quarter earnings that, despite showing a 53% year-over-year increase in ANKTIVA sales to $48.7 million, missed Wall Street estimates and declined from the previous quarter's revenue. The company reported widening losses, with research and development costs rising to $71.5 million, contributing to an adjusted quarterly loss of $97.9 million. The market reaction reflects concerns over high valuation multiples and liquidity risks. ImmunityBio has issued a 'substantial doubt' warning regarding its ability to continue as a going concern without additional funding, noting that current cash reserves may only last slightly more than four quarters at the present burn rate. However, potential growth remains tied to an upcoming year-end FDA filing intended to expand ANKTIVA's usage to earlier stages of bladder cancer.
Tickers: $IBRX
Topics: FDA filing going concern doubt immunotherapy quarterly earnings revenue miss
Read the full article at Motley Fool
Part of the story AAON Shares Surge 22% Following Third-Quarter Earnings Beat and Raised Full-Year Guidance (29 articles)